Now showing items 1-20 of 92

    • 11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial. 

      Cameron, D; Piccart-Gebhart, MJ; Gelber, RD; Procter, M; Goldhirsch, A; de Azambuja, E; Castro, G; Untch, M; Smith, I; Gianni, L; Baselga, J; Al-Sakaff, N; Lauer, S; McFadden, E; Leyland-Jones, B; Bell, R; Dowsett, M; Jackisch, C; Herceptin Adjuvant (HERA) Trial Study Team (2017-03)
      BACKGROUND:Clinical trials have shown that trastuzumab, a recombinant monoclonal antibody against HER2 receptor, significantly improves overall survival and disease-free survival in women with HER2-positive early breast ...
    • Accelerated versus standard epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil or capecitabine as adjuvant therapy for breast cancer in the randomised UK TACT2 trial (CRUK/05/19): a multicentre, phase 3, open-label, randomised, controlled trial. 

      Cameron, D; Morden, JP; Canney, P; Velikova, G; Coleman, R; Bartlett, J; Agrawal, R; Banerji, J; Bertelli, G; Bloomfield, D; Brunt, AM; Earl, H; Ellis, P; Gaunt, C; Gillman, A; Hearfield, N; Laing, R; Murray, N; Couper, N; Stein, RC; Verrill, M; Wardley, A; Barrett-Lee, P; Bliss, JM; TACT2 Investigators (2017-07)
      BACKGROUND: Adjuvant chemotherapy for early breast cancer has improved outcomes but causes toxicity. The UK TACT2 trial used a 2×2 factorial design to test two hypotheses: whether use of accelerated epirubicin would improve ...
    • Active surveillance in metastatic renal-cell carcinoma: a prospective, phase 2 trial. 

      Rini, BI; Dorff, TB; Elson, P; Rodriguez, CS; Shepard, D; Wood, L; Humbert, J; Pyle, L; Wong, Y-N; Finke, JH; Rayman, PA; Larkin, JMG; Garcia, JA; Plimack, ER (2016-09)
      A subset of patients with metastatic renal-cell carcinoma show indolent growth of metastases. Because of the toxicity and non-curative nature of systemic therapy, some of these patients could benefit from initial active ...
    • Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocol. 

      Sydes, MR; Spears, MR; Mason, MD; Clarke, NW; Dearnaley, DP; de Bono, JS; Attard, G; Chowdhury, S; Cross, W; Gillessen, S; Malik, ZI; Jones, R; Parker, CC; Ritchie, AWS; Russell, JM; Millman, R; Matheson, D; Amos, C; Gilson, C; Birtle, A; Brock, S; Capaldi, L; Chakraborti, P; Choudhury, A; Evans, L; Ford, D; Gale, J; Gibbs, S; Gilbert, DC; Hughes, R; McLaren, D; Lester, JF; Nikapota, A; O'Sullivan, J; Parikh, O; Peedell, C; Protheroe, A; Rudman, SM; Shaffer, R; Sheehan, D; Simms, M; Srihari, N; Strebel, R; Sundar, S; Tolan, S; Tsang, D; Varughese, M; Wagstaff, J; Parmar, MKB; James, ND; STAMPEDE Investigators (2018-05)
      Background:Adding abiraterone acetate with prednisolone (AAP) or docetaxel with prednisolone (DocP) to standard-of-care (SOC) each improved survival in systemic therapy for advanced or metastatic prostate cancer: evaluation ...
    • Adding Celecoxib With or Without Zoledronic Acid for Hormone-Naïve Prostate Cancer: Long-Term Survival Results From an Adaptive, Multiarm, Multistage, Platform, Randomized Controlled Trial. 

      Mason, MD; Clarke, NW; James, ND; Dearnaley, DP; Spears, MR; Ritchie, AWS; Attard, G; Cross, W; Jones, RJ; Parker, CC; Russell, JM; Thalmann, GN; Schiavone, F; Cassoly, E; Matheson, D; Millman, R; Rentsch, CA; Barber, J; Gilson, C; Ibrahim, A; Logue, J; Lydon, A; Nikapota, AD; O'Sullivan, JM; Porfiri, E; Protheroe, A; Srihari, NN; Tsang, D; Wagstaff, J; Wallace, J; Walmsley, C; Parmar, MKB; Sydes, MR; STAMPEDE Investigators (2017-05)
      Purpose Systemic Therapy for Advanced or Metastatic Prostate Cancer: Evaluation of Drug Efficacy is a randomized controlled trial using a multiarm, multistage, platform design. It recruits men with high-risk, locally ...
    • Adherence to Guidelines for Adult (Non-GIST) Soft Tissue Sarcoma in the Netherlands: A Plea for Dedicated Sarcoma Centers. 

      Hoekstra, HJ; Haas, RLM; Verhoef, C; Suurmeijer, AJH; van Rijswijk, CSP; Bongers, BGH; van der Graaf, WT; Ho, VKY (2017-10)
      Optimal management of soft tissue sarcoma (STS) remains a challenge. A nationwide survey assessed the quality of STS care in the Netherlands, thereby aiming to identify potentialities for improvement through more centralized ...
    • Adjuvant bevacizumab for melanoma patients at high risk of recurrence: survival analysis of the AVAST-M trial. 

      Corrie, PG; Marshall, A; Nathan, PD; Lorigan, P; Gore, M; Tahir, S; Faust, G; Kelly, CG; Marples, M; Danson, SJ; Marshall, E; Houston, SJ; Board, RE; Waterston, AM; Nobes, JP; Harries, M; Kumar, S; Goodman, A; Dalgleish, A; Martin-Clavijo, A; Westwell, S; Casasola, R; Chao, D; Maraveyas, A; Patel, PM; Ottensmeier, CH; Farrugia, D; Humphreys, A; Eccles, B; Young, G; Barker, EO; Harman, C; Weiss, M; Myers, KA; Chhabra, A; Rodwell, SH; Dunn, JA; Middleton, MR; AVAST-M Investigators; Nathan, P; Lorigan, P; Dziewulski, P; Holikova, S; Panwar, U; Tahir, S; Faust, G; Thomas, A; Corrie, P; Sirohi, B; Kelly, C; Middleton, M; Marples, M; Danson, S; Lester, J; Marshall, E; Ajaz, M; Houston, S; Board, R; Eaton, D; Waterston, A; Nobes, J; Loo, S; Gray, G; Stubbings, H; Gore, M; Harries, M; Kumar, S; Goodman, A; Dalgleish, A; Martin-Clavijo, A; Marsden, J; Westwell, S; Casasola, R; Chao, D; Maraveyas, A; Marshall, E; Patel, P; Ottensmeier, C; Farrugia, D; Humphreys, A; Eccles, B; Dega, R; Herbert, C; Price, C; Brunt, M; Scott-Brown, M; Hamilton, J; Hayward, RL; Smyth, J; Woodings, P; Nayak, N; Burrows, L; Wolstenholme, V; Wagstaff, J; Nicolson, M; Wilson, A; Barlow, C; Scrase, C; Podd, T; Gonzalez, M; Stewart, J; Highley, M; Wolstenholme, V; Grumett, S; Goodman, A; Talbot, T; Nathan, K; Coltart, R; Gee, B; Gore, M; Farrugia, D; Martin-Clavijo, A; Marsden, J; Price, C; Farrugia, D; Nathan, K; Coltart, R; Nathan, K; Coltart, R (2018-08)
      Background:Bevacizumab is a recombinant humanised monoclonal antibody to vascular endothelial growth factor shown to improve survival in advanced solid cancers. We evaluated the role of adjuvant bevacizumab in melanoma ...
    • Age-related sarcoma patient experience: results from a national survey in England. 

      Younger, E; Husson, O; Bennister, L; Whelan, J; Wilson, R; Roast, A; Jones, RL; van der Graaf, WT (2018-10-17)
      BACKGROUND:Sarcomas are rare, heterogeneous tumours affecting patients of any age. Previous surveys describe that sarcoma patients report a significantly worse experience than those with common cancers. Consequently, Sarcoma ...
    • Analgesic Use and Ovarian Cancer Risk: An Analysis in the Ovarian Cancer Cohort Consortium. 

      Trabert, B; Poole, EM; White, E; Visvanathan, K; Adami, H-O; Anderson, GL; Brasky, TM; Brinton, LA; Fortner, RT; Gaudet, M; Hartge, P; Hoffman-Bolton, J; Jones, M; Lacey, JV; Larsson, SC; Mackenzie, GG; Schouten, LJ; Sandler, DP; O'Brien, K; Patel, AV; Peters, U; Prizment, A; Robien, K; Setiawan, VW; Swerdlow, A; van den Brandt, PA; Weiderpass, E; Wilkens, LR; Wolk, A; Wentzensen, N; Tworoger, SS; Ovarian Cancer Cohort Consortium (OC3) (2019-02)
      BACKGROUND:Aspirin use is associated with reduced risk of several cancers. A pooled analysis of 12 case-control studies showed a 10% decrease in ovarian cancer risk with regular aspirin use, which was stronger for daily ...
    • Assessing methods for dealing with treatment switching in clinical trials: A follow-up simulation study. 

      Latimer, NR; Abrams, KR; Lambert, PC; Morden, JP; Crowther, MJ (2018-03)
      When patients randomised to the control group of a randomised controlled trial are allowed to switch onto the experimental treatment, intention-to-treat analyses of the treatment effect are confounded because the separation ...
    • Ataxia Telangiectasia Mutated Protein Loss and Benefit From Oxaliplatin-based Chemotherapy in Colorectal Cancer. 

      Sundar, R; Miranda, S; Rodrigues, DN; Chénard-Poirier, M; Dolling, D; Clarke, M; Figueiredo, I; Bertan, C; Yuan, W; Ferreira, A; Chistova, R; Boysen, G; Perez, DR; Tunariu, N; Mateo, J; Wotherspoon, A; Chau, I; Cunningham, D; Valeri, N; Carreira, S; de Bono, J (2018-12)
      BACKGROUND:Loss of ataxia telangiectasia mutated (ATM), a key protein regulating DNA repair signaling, has been suggested to increase sensitivity to DNA damaging agents. We conducted a study analyzing the loss of ATM protein ...
    • Best time to assess complete clinical response after chemoradiotherapy in squamous cell carcinoma of the anus (ACT II): a post-hoc analysis of randomised controlled phase 3 trial. 

      Glynne-Jones, R; Sebag-Montefiore, D; Meadows, HM; Cunningham, D; Begum, R; Adab, F; Benstead, K; Harte, RJ; Stewart, J; Beare, S; Hackshaw, A; Kadalayil, L; ACT II study group (2017-03)
      Guidelines for anal cancer recommend assessment of response at 6-12 weeks after starting treatment. Using data from the ACT II trial, we determined the optimum timepoint to assess clinical tumour response after ...
    • Bilateral mammoplasty for cancer: Surgical, oncological and patient-reported outcomes. 

      Di Micco, R; O'Connell, RL; Barry, PA; Roche, N; MacNeill, FA; Rusby, JE (2017-01)
      Bilateral mammoplasty (BM) can optimise oncological safety and aesthetic outcomes in women with large or ptotic breasts whose tumour to breast volume ratio or tumour location pose a challenge to standard breast-conserving ...
    • The biological, clinical and prognostic implications of p53 transcriptional pathways in breast cancers. 

      Abdel-Fatah, TM; Powe, DG; Agboola, J; Adamowicz-Brice, M; Blamey, RW; Lopez-Garcia, MA; Green, AR; Reis-Filho, JS; Ellis, IO (2010-03)
      We hypothesized that the functional status of p53 transcriptional pathways, rather than p53 protein expression alone, could accurately discriminate between low- and high-risk breast carcinoma (BC) and inform about individuals' ...
    • Breast cancer risk in relation to history of preeclampsia and hyperemesis gravidarum: Prospective analysis in the Generations Study. 

      Wright, LB; Schoemaker, MJ; Jones, ME; Ashworth, A; Swerdlow, AJ (2018-08)
      Preeclampsia and hyperemesis gravidarum are pregnancy complications associated with altered sex hormone levels. Previous studies suggest preeclampsia may be associated with a decreased risk of subsequent breast cancer and ...
    • Busulfan and melphalan versus carboplatin, etoposide, and melphalan as high-dose chemotherapy for high-risk neuroblastoma (HR-NBL1/SIOPEN): an international, randomised, multi-arm, open-label, phase 3 trial. 

      Ladenstein, R; Pötschger, U; Pearson, ADJ; Brock, P; Luksch, R; Castel, V; Yaniv, I; Papadakis, V; Laureys, G; Malis, J; Balwierz, W; Ruud, E; Kogner, P; Schroeder, H; de Lacerda, AF; Beck-Popovic, M; Bician, P; Garami, M; Trahair, T; Canete, A; Ambros, PF; Holmes, K; Gaze, M; Schreier, G; Garaventa, A; Vassal, G; Michon, J; Valteau-Couanet, D; SIOP Europe Neuroblastoma Group (SIOPEN) (2017-04)
      High-dose chemotherapy with haemopoietic stem-cell rescue improves event-free survival in patients with high-risk neuroblastoma; however, which regimen has the greatest patient benefit has not been established. We aimed ...
    • Characterizing and targeting PDGFRA alterations in pediatric high-grade glioma. 

      Koschmann, C; Zamler, D; MacKay, A; Robinson, D; Wu, Y-M; Doherty, R; Marini, B; Tran, D; Garton, H; Muraszko, K; Robertson, P; Leonard, M; Zhao, L; Bixby, D; Peterson, L; Camelo-Piragua, S; Jones, C; Mody, R; Lowenstein, PR; Castro, MG (2016-10)
      Pediatric high-grade glioma (HGG, WHO Grade III and IV) is a devastating brain tumor with a median survival of less than two years. PDGFRA is frequently mutated/ amplified in pediatric HGG, but the significance of this ...
    • Cholesterol, Cholesterol-Lowering Medication Use, and Breast Cancer Outcome in the BIG 1-98 Study. 

      Borgquist, S; Giobbie-Hurder, A; Ahern, TP; Garber, JE; Colleoni, M; Láng, I; Debled, M; Ejlertsen, B; von Moos, R; Smith, I; Coates, AS; Goldhirsch, A; Rabaglio, M; Price, KN; Gelber, RD; Regan, MM; Thürlimann, B (2017-04)
      Purpose Cholesterol-lowering medication (CLM) has been reported to have a role in preventing breast cancer recurrence. CLM may attenuate signaling through the estrogen receptor by reducing levels of the estrogenic cholesterol ...
    • Circulating tumour cell increase as a biomarker of disease progression in metastatic castration-resistant prostate cancer patients with low baseline CTC counts. 

      Lorente, D; Olmos, D; Mateo, J; Dolling, D; Bianchini, D; Seed, G; Flohr, P; Crespo, M; Figueiredo, I; Miranda, S; Scher, HI; Terstappen, LWMM; de Bono, JS (2018-07)
      Background:The development of treatment response and surrogate biomarkers for advanced prostate cancer care is an unmet clinical need. Patients with baseline circulating tumour cell (BLCTCs) counts <5/7.5 mL represent a ...
    • Circulating Vitamin D and Colorectal Cancer Risk: An International Pooling Project of 17 Cohorts. 

      McCullough, ML; Zoltick, ES; Weinstein, SJ; Fedirko, V; Wang, M; Cook, NR; Eliassen, AH; Zeleniuch-Jacquotte, A; Agnoli, C; Albanes, D; Barnett, MJ; Buring, JE; Campbell, PT; Clendenen, TV; Freedman, ND; Gapstur, SM; Giovannucci, EL; Goodman, GG; Haiman, CA; Ho, GYF; Horst, RL; Hou, T; Huang, W-Y; Jenab, M; Jones, ME; Joshu, CE; Krogh, V; Lee, I-M; Lee, JE; Männistö, S; Le Marchand, L; Mondul, AM; Neuhouser, ML; Platz, EA; Purdue, MP; Riboli, E; Robsahm, TE; Rohan, TE; Sasazuki, S; Schoemaker, MJ; Sieri, S; Stampfer, MJ; Swerdlow, AJ; Thomson, CA; Tretli, S; Tsugane, S; Ursin, G; Visvanathan, K; White, KK; Wu, K; Yaun, S-S; Zhang, X; Willett, WC; Gail, MH; Ziegler, RG; Smith-Warner, SA (2019-02)
      BACKGROUND:Experimental and epidemiological studies suggest a protective role for vitamin D in colorectal carcinogenesis, but evidence is inconclusive. Circulating 25-hydroxyvitamin D (25(OH)D) concentrations that minimize ...